These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 24524730)

  • 21. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
    Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
    Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
    Larsen CM; Faulenbach M; Vaag A; Vølund A; Ehses JA; Seifert B; Mandrup-Poulsen T; Donath MY
    N Engl J Med; 2007 Apr; 356(15):1517-26. PubMed ID: 17429083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors.
    Davidson JA
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S28-38. PubMed ID: 19952301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
    Ahn CH; Oh TJ; Kwak SH; Cho YM
    Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S; Matsui T
    Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
    Wu W; Li Y; Chen X; Lin D; Xiang S; Shen F; Gu X
    Med Sci Monit; 2015 Sep; 21():2678-84. PubMed ID: 26350766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
    Seino Y; Kuwata H; Yabe D
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
    Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Deacon CF
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
    Gastaldelli A; Balas B; Ratner R; Rosenstock J; Charbonnel B; Bolli GB; Boldrin M; Balena R
    Diabetes Obes Metab; 2014 Feb; 16(2):170-8. PubMed ID: 23911196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
    van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
    Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Derosa G; Carbone A; Franzetti I; Querci F; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
    Ionut V; Woolcott OO; Mkrtchyan HJ; Stefanovski D; Kabir M; Iyer MS; Liu H; Castro AV; Wu Q; Broussard JL; Kolka CM; Asare-Bediako I; Bergman RN
    PLoS One; 2016; 11(7):e0158703. PubMed ID: 27398720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
    Van Gaal LF; Gutkin SW; Nauck MA
    Eur J Endocrinol; 2008 Jun; 158(6):773-84. PubMed ID: 18322302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp.
    Zhang Y; Chi J; Wang W; Hong J; Gu W; Wang B; Ning G
    J Diabetes; 2015 Mar; 7(2):213-21. PubMed ID: 24889731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating insulin sensitivity and β-cell function from the oral glucose tolerance test: validation of a new insulin sensitivity and secretion (ISS) model.
    Ha J; Chung ST; Springer M; Kim JY; Chen P; Chhabra A; Cree MG; Diniz Behn C; Sumner AE; Arslanian SA; Sherman AS
    Am J Physiol Endocrinol Metab; 2024 Apr; 326(4):E454-E471. PubMed ID: 38054972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin sensitivity, and β-cell function in relation to hemoglobin A1C.
    Marini MA; Frontoni S; Succurro E; Arturi F; Sciacqua A; Hribal ML; Perticone F; Sesti G
    Nutr Metab Cardiovasc Dis; 2014 Jan; 24(1):27-33. PubMed ID: 23601331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating type 2 diabetes: incretin mimetics and enhancers.
    Janosz KE; Zalesin KC; Miller WM; McCullough PA
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):387-95. PubMed ID: 19808944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.